Why is "BPL-003" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-23 00:20:05
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
BPL-003 entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-23 and was most recently seen on 2026-07-23.
Wikipedia Overview
5-MeO-DMT, also known as 5-methoxy-N,N-dimethyltryptamine, as well as O-methylbufotenin or mebufotenin, is an atypical psychedelic drug, entheogen, and alkaloid of the tryptamine and 5-methoxytryptamine families. It is found naturally in a wide variety of plant species, and is also secreted by the glands of at least one toad species, the Colorado River toad. It may occur naturally in humans as well. Like its close relatives dimethyltryptamine (DMT) and bufotenin (5-HO-DMT), it has been used as an entheogen in South America. Slang terms include five-methoxy, the power, bufo, and toad venom. The drug has been described as the most powerful psychedelic and, by journalist Michael Pollan, as the "Mount Everest of psychedelics".
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Weekly Recap: Eli Lilly acquisition of AtaiBeckley and BPL-003 Phase 3 - TradingView
-
The market for psychedelic drugs to treat mental health conditions gets a big buy signal - CNBC
-
BPL-003 for Treatment Resistant Depression Continues to Show Sustained Symptom Reduction - Psychiatric Times
-
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions - PR Newswire
-
StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley a Good Trip for Psychedelic Drugs, Analysts and Investors Agree - Genetic Engineering and Biotechnology News
-
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - Reuters
-
Is AtaiBeckley’s BPL-003 Phase 3 Launch Altering The Investment Case For AtaiBeckley (ATAI)? - Yahoo Finance
-
Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition - MedCity News
-
Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market - Fierce Biotech
-
AtaiBeckley (ATAI) Advances BPL 003 Into Phase III For Treatment Resistant Depression - simplywall.st
-
Lilly to Acquire AtaiBeckley - Contract Pharma
-
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal - Psychedelic Alpha
-
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction - CNBC
-
BPL-003 Nasal Spray Shows Quick and Enduring Effect in Treatment-Resistant Depression - Psychiatric Times
-
AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus - Yahoo Finance
-
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout - TradingView
-
Is AtaiBeckley (NasdaqGM:ATAI) Overvalued After FDA Support For BPL 003? - simplywall.st
-
Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003’s Phase 3 Readiness - Yahoo Finance
-
AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support - Yahoo Finance
-
AtaiBeckley Deepens BPL-003 Focus Raising Questions On Valuation Gap - Yahoo Finance
-
Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion - Psychedelic Alpha
-
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - Yahoo Finance
-
ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly - TradingView
-
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003? - Yahoo Finance
-
AtaiBeckley (ATAI) Jefferies Global Healthcare Conference 2026 Summary - Quartr
-
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD (NASDAQ:ATAI) - Seeking Alpha
-
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update - Investing News Network
-
AtaiBeckley climbs after kicking off Phase 3 for BPL-003 in depression - TechStock²
-
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - Investing News Network
-
AtaiBeckley stock is soaring, and it has Eli Lilly to thank - TradingView
-
AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances - Yahoo Finance
-
AtaiBeckley (ATAI) Agrees To Eli Lilly Buyout With Milestone Upside For Shareholders - Sahm
-
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - Bloomberg.com
-
Single-dose nasal spray eases treatment-resistant depression in 12-patient trial - Stock Titan
-
AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish (NASDAQ:ATAI) - Seeking Alpha
-
AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 - Yahoo Finance
-
ATAI: BPL-003 enters phase III for depression, with top-line data expected in early 2029 - TradingView
-
AtaiBeckley to discuss Phase 3 BPL-003 program at multiple June investor conferences - TradingView
-
AtaiBeckley Announces Positive Topline Data from the Phase - GlobeNewswire
-
AtaiBeckley Inc. (NASDAQ:ATAI) stock jumps as FDA staffing guidance spotlights BPL-003’s two-hour edge - TechStock²
-
atai Life Sciences and Beckley Psytech Announce U.S. FDA - GlobeNewswire
-
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression - GlobeNewswire
-
AtaiBeckley to Join Russell 2000 and Russell 3000 Indexes in 2026 Reconstitution | ATAI Stock News - Quiver Quantitative
-
Atai Life Sciences (ATAI): Evaluating Valuation After FDA Breakthrough Therapy Designation for BPL-003 - Yahoo Finance
-
Deutsche Bank Confident of AtaiBeckley Inc. (ATAI) Growth Prospects on Psychedelic Medicines - Yahoo Finance
-
Eli Lilly’s $3.8 Billion Psychedelic Bet Puts Atai Beckley in a Holding Pattern - Ad-hoc-news.de
-
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing - Yahoo! Finance Canada
-
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression - Investing News Network
-
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression - Slideshow (NASDAQ:ATAI) 2025-11-10 - Seeking Alpha
-
Positive Results From the Phase 2b Study of BPL-003 in Patients With Treatment-Resistant Depression - Psychiatric Times
-
Psychedelic Readout Tracker - Psychedelic Alpha
-
ATAI Stock Pops As BPL-003 Data, Index Additions Fuel Momentum - StocksToTrade
-
November in Review: Updates on the Psychiatric Treatment Pipeline - Psychiatric Times
-
Lilly's $3.8B Psychedelic Bet Turns Atai Beckley Into a Milestone-Linked Payout Story - Ad-hoc-news.de
-
AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3 - Psychedelic Alpha
-
AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - Investing News Network
-
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference - Investing News Network
-
ATAI Stock Surges As BPL-003 Momentum And Policy Tailwinds Build - timothysykes.com
-
Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition - inkl
-
Trump Signed a Psychedelic Drugs Order—and These 4 Stocks Surged - Barron's
-
ATAI Stock Soars On Track For Best Day On Trump Psychedelics Push And Wall Street Cheers - Stocktwits
-
atai and Beckley’s psychedelic advances to pivotal TRD trial - Clinical Trials Arena
-
ATAI focuses on psychedelics biotech with key P... - Pluang
-
Breakthrough therapy designation for atai/Beckley 5-MeO-DMT drug; both ketamine and active placebo improve depression symptoms; and ketamine company to receive priority FDA review - The Microdose | Substack
-
AtaiBeckley weighing options for psychedelic drug (ATAI:NASDAQ) - Seeking Alpha
-
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation - Investing News Network
-
Psychedelic merger to create AtaiBeckley completes - pharmaphorum
-
BPL-003 for Alcohol Use Disorder: Positive Topline Results of Phase 2A Study - Psychiatric Times
-
BLP-003 for Treatment-Resistant Depression: Phase 2b Patient Enrollment Completed - Psychiatric Times
-
First Participant Dosed in Study of BPL-003 Neurophysiological Effects - Psychiatric Times
-
Beckley’s Psychedelic Nasal Spray Clears Phase II Depression Study - BioSpace
-
atai and Beckley Psytech’s psychedelic wins in Phase IIb depression trial - Clinical Trials Arena
-
Publication of Phase 1 Results Announced for BPL-003 - Psychiatric Times
-
Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study - Psychedelic Alpha
-
Beckley's psychedelic med inches forward in depression - pharmaphorum
-
Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More - BioSpace
-
atai Life Sciences Announces Completion of Enrollment in - GlobeNewswire
-
Beckley announces new results for 5-MeO-DMT drug; Updates on psychedelics and the Trump Administration; Data and lessons from Health Canada’s psilocybin access program - The Microdose | Substack
-
Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering Atai merger - Fierce Biotech
-
Atai & Beckley Psychedelic Merger Creates Global Mental Health Leader - The Clinical Trial Vanguard
-
Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model - Psychedelic Alpha
-
Beckley Psytech reports initial positive data from TRD treatment trial - Clinical Trials Arena
-
Atai in $370M merger deal with psychedelic drug specialist Beckley - BioWorld News
-
A Promising Depression Drug Works. Psychedelics Are Back. - Barron's
-
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - GlobeNewswire
-
First Patient Dosed in Study To Unravel “Mystical Experiences” of Psychedelic Derived From Toad Skin - Technology Networks
-
No serious adverse reactions recorded in synthetic 5-MeO-DMT study; California psychedelics bill advances; Are medical trainees ready for psychedelics? - The Microdose | Substack
-
BPL 3 - Tribune242
-
Eli Lilly Acquires Psychedelic Drugmaker AtaiBeckley in KES 364 Billion Deal - streamlinefeed.co.ke
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.